Images List Premium Download Classic

G Proteins

G Proteins-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Novel dna-binding proteins and uses thereof
Sangamo Therapeutics, Inc.
January 11, 2018 - N°20180010152

Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel dna-binding domains, including tale dna-binding domains. Also disclosed are methods of using these novel dna-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
Compositions and methods for protein glycosylation
Glaxosmithkline Biologicals, Sa
January 04, 2018 - N°20180002679

Described herein are oligosaccharyl transferases for use in n-glycosylating proteins of interest in vitro and in host cells. Methods for using such oligosaccharyl transferases, nucleic acids encoding such oligosaccharyl transferases, and host cells comprising such oligosaccharyl transferases are also provided herein. Glycoconjugates generated by using such oligosaccharyl transferases are also provided herein.
Plasma kallikrein binding proteins
Dyax Corp.
January 04, 2018 - N°20180002449

Plasma kallikrein binding proteins and methods of using such proteins are described.
G Proteins Patent Pack
Download 271+ patent application PDFs
G Proteins Patent Applications
Download 271+ G Proteins-related PDFs
For professional research & prior art discovery
inventor
  • 271+ full patent PDF documents of G Proteins-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Plasma kallikrein binding proteins
Dyax Corp.
January 04, 2018 - N°20180002447

Plasma kallikrein binding proteins and methods of using such proteins are described.
Antibodies to matrix metalloproteinase 9
Gilead Biologics, Inc.
January 04, 2018 - N°20180002446

The present disclosure provides compositions and methods of use involving binding proteins, e. G., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), such as where the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).
Oncostatin m receptor antigen binding proteins
Kiniksa Pharmaceuticals, Ltd.
January 04, 2018 - N°20180002429

The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins, e. G., antibodies and functional fragments, derivatives, muteins, and variants thereof. Osmr antigen binding proteins interfere with binding of osm and/or il-31 to osmr. In some embodiments, anti-osmr antigen binding proteins are useful tools in studying diseases and disorders associated with osmr and are particularly useful in ...
G Proteins Patent Pack
Download 271+ patent application PDFs
G Proteins Patent Applications
Download 271+ G Proteins-related PDFs
For professional research & prior art discovery
inventor
  • 271+ full patent PDF documents of G Proteins-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for selecting a single cell expressing a heterogeneous combination of antibodies
Merus N.v.
January 04, 2018 - N°20180002404

The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having ...
Feed media
Amgen Inc.
December 28, 2017 - N°20170369837

The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.
Mice expressing a limited immunoglobulin light chain repertoire
Regeneron Pharmaceuticals, Inc.
December 28, 2017 - N°20170369593

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene ...
Single chain variable fragment cd3 binding proteins
Harpoon Therapeutics, Inc.
December 28, 2017 - N°20170369575

Disclosed herein are single chain variable fragment cd3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment cd3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
Single domain serum albumin binding protein
Harpoon Therapeutics, Inc.
December 28, 2017 - N°20170369563

Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
Method of treating pancreatic cancer
Chemocentryx, Inc.
December 28, 2017 - N°20170368043

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
Use of enzymatically hydrolyzed vegetable protein in brewing fermented beverages
Corn Products Development, Inc.
December 28, 2017 - N°20170367396

This invention provides methods to reduce fermentation time of the cereal based fermented beverages such as beer, increasing the cellar output as well as enhancing yeast nutrition and beer foam quality. An enzymatically hydrolyzed vegetable protein which supplies a balanced combination of foam enhancing proteins and free amino acids of high nutritional value for yeast is added to the materials ...
G Proteins Patent Pack
Download 271+ patent application PDFs
G Proteins Patent Applications
Download 271+ G Proteins-related PDFs
For professional research & prior art discovery
inventor
  • 271+ full patent PDF documents of G Proteins-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and products for expressing proteins in cells
Factor Bioscience Inc.
December 21, 2017 - N°20170362612

The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a ...
Use of non-subtype b gag proteins for lentiviral packaging
Institut Pasteur
December 21, 2017 - N°20170362607

The invention encompasses a lentiviral packaging vector comprising a non-subtype b gag-pol sequence, particularly a subtype d gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising hiv-1 non-subtype b gag and/or pol proteins.
Method for stabilizing proteins
Lonza Ltd
December 14, 2017 - N°20170356022

The present disclosure features methods and compositions for increasing the amount of products of cellular metabolism, e. G., proteins, by lowering the temperature of cells expressing the product at one or more steps while culturing the cells, expressing the product, and/or recovering the product.
Method of treating pancreatic cancer
Chemocentryx, Inc.
December 14, 2017 - N°20170354657

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
Using programmable dna binding proteins to enhance targeted genome modification
Sigma-aldrich Co., Llc
December 07, 2017 - N°20170349913

Compositions and methods for using programmable dna binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
Chemistry, systems and methods of translocation of a polymer through a nanopore
Arizona Board Of Regents On Behalf Of Arizona State University
November 30, 2017 - N°20170343558

Embodiments disclosed herein are directed to recognition tunneling systems, methods and devices, and more particularly, to chemical reactions for selectively labeling proteins and peptides and placing protein and/or peptides into, or onto a nanopore formed in a solid support and threading such in and/or through the nanopore, with such nanopores, in some embodiments, including a molecular motor to ...
Bispecific binding proteins
Abbvie Biotherapeutics Inc.
November 30, 2017 - N°20170342169

The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.
Methods and compositions relating to anti-ccr7 antigen binding proteins
Amgen Inc.
November 30, 2017 - N°20170342155

The present invention provides compositions and methods relating to antigen binding proteins against ccr7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
Loading